Before the Bell Scans of Affymax, Questcor Pharma, Gilead Sciences, Vertex Pharma, and Optimer Pharma

  Before the Bell Scans of Affymax, Questcor Pharma, Gilead Sciences, Vertex
                          Pharma, and Optimer Pharma

PR Newswire

LONDON, March 1, 2013

LONDON, March 1, 2013 /PRNewswire/ --

The Dow Jones ended the day 0.15 percent lower at 14,054.49, while the S&P 500
closed at 1,514.68, down 0.09 percent. NASDAQ also followed suit closing the
day at 3,160.19, down 0.07 percent. Markets made some gains in the earlier
part of the trading session but gave those up following news about economic
growth in fourth quarter. In light of this, our research team took a look at
the healthcare sector including major companies like Affymax Inc. (NASDAQ:
AFFY), Questcore Pharmaceuticals Inc. (NASDAQ: QCOR), Gilead Sciences Inc.
(NASDAQ: GILD), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) and Optimer
Pharmaceuticals Inc. (NASDAQ: OPTR). StockCall has taken an interest in these
companies and you can now sign up to download the free technical research on

Affymax's stock finished 0.75 percent lower at $2.65 with volume up from daily
average of 3.93 million to 6.81 million. The stock has had a dismal run so far
in 2013 with its year-to-date loss at 86 percent. It currently shows bearish
trend which is further confirmed by its MACD chart. Affymax has its first
support level at $2.55. In the coming trading sessions, the stock is likely to
go as high as $2.67. Sign up today to read the free research report on AFFY at 

Questcore Pharmaceuticals stock dropped in its previous trading session. The
stock closed 1.21 percent lower at $32.60 with 1.79 million share volume.
Despite the significant upward movement, it is still up more than 22 percent
for the year. In the past 52 weeks, Questcore is down 16.2 percent. The stock
currently has support at $32.35 level. The stock's MACD chart shows bullish
trend and it may face its first resistance level at $32.75. Upon breaching
this level, the stock may go as high as $32.95. Register to download the free
technical analysis on QCOR at 

Gilead Sciences is currently in a neutral mode as the stock ended Thursday's
trading session at $42.72, down 0.40 percent. The stock traded in the range of
$42.71 and $43.18 during the session. Its first support level is at $42.31 and
upon breaching this level, the stock may go down to $41.78 level. On the
upside, the biotech's stock may touch $43.14 level. The company's stock has
traded in the range of $22.40 and $43.35 in the past 52 weeks and it grew by
88.78 percent during the same time period. Free report on GILD can be accessed
by registering at 

Vertex's shares traded lower for its latest trading session, ending the day
0.32 percent lower at $46.82. The stock fell to an intra-day low of $46.59,
while its intra-day high stood at $48.15. Despite the downward movement,
Vertex gained more than 11 percent this year, compared to a gain of 6.2
percent for the S&P 500. The stock has strong support at around $46.25, as it
shows a neutral trend. The stock is trading higher than its 20-day and 50-day
moving averages. Register with StockCall and download the research on VRTX for
free at  

Optimer Pharma traded in the range of $11.78 and $12.20 in yesterday's trading
session and ended the day at $12.12, down 0.08 percent. The stock's 52 weeks
range stands at $8.64 and $16.49. Optimer has lost 4.57 percent of its value
in the past 12 months, while it gained 33.92 percent so far this year. The
biotech company is in a neutral mode and may find its first support level at
$11.72. It is trading above its 20-day moving average of $10.98. Read the full
free research on OPTR by signing up to StockCall at 

About is a financial website where investors can have easy, precise
and comprehensive research and opinions on stocks making the headlines. Sign
up today to talk to our financial analyst at 


Contact: Contact Person:William T. Knight, Email:, Contact
Number: +1(646)396-9857 (9:00 am EST - 01:30 pm EST)
Press spacebar to pause and continue. Press esc to stop.